CSL Ltd. (CSLLY) Stock Price & How to Invest

CSL Limited is one of the world's largest biotechnology companies and is listed on the Australian Securities Exchange, with US investors able to hold it through the CSLLY American Depositary Receipt. The group runs three businesses. CSL Behring, the largest at roughly US$11.4 billion of FY26 revenue, collects blood plasma through one of the biggest donor-center networks in the world and fractionates it into therapies such as immunoglobulins (used for immune deficiencies and neurological conditions), albumin, haemophilia treatments and specialty products like the gene therapy HEMGENIX and the hereditary angioedema drug ANDEMBRY. CSL Seqirus, at about US$2.0 billion, is one of the largest influenza vaccine makers globally, with egg-based, cell-based and adjuvanted vaccines and a pandemic-preparedness role for several governments. CSL Vifor, at about US$2.4 billion, sells iron-deficiency and kidney-disease medicines and came with the roughly US$11.7 billion acquisition of Vifor Pharma in 2022. CSL reports in US dollars even though its home listing is in Australian dollars.

The investment picture changed sharply over the last 18 months. CSL shares fell from above A$270 in August 2025 to a low near A$90 in mid 2026, the worst stretch in the company's modern history. The slide came in stages: an August 2025 result that cut growth expectations and announced a Seqirus demerger, the shelving of that demerger in October 2025 as US vaccination rates fell, the abrupt February 2026 departure of CEO Paul McKenzie (the board said the company needed broader skills), and a May 2026 review by interim CEO Gordon Naylor that downgraded guidance and flagged multibillion dollar writedowns. The FY26 result in August 2026 confirmed a statutory loss of about US$2.6 billion after roughly US$7.1 billion of pre-tax impairments, mostly against Vifor, but underlying profit held up better than feared and FY27 guidance of about 5% underlying NPAT growth came in above consensus. The shares jumped around 17% on the day and have since traded near A$185, roughly double the low but still about a third below the 2025 level. The open questions are how fast immunoglobulin demand and plasma margins recover, how steep the Vifor decline becomes, and who the board picks as permanent CEO.

The most immediate risk is that immunoglobulin demand stays soft or that competitors such as Grifols, Takeda and Octapharma price aggressively, which would undercut the FY27 guidance the recent rebound is built on. US policy is a second risk: Medicare drug pricing changes, potential pharmaceutical tariffs, and a federal stance that has lowered flu vaccination rates all hit CSL directly, since the US is its largest market. Execution risk is elevated because the company is mid-restructuring with an interim CEO, and a permanent leader may reset strategy, guidance or capital allocation again. China cost-containment measures have already cut albumin sales about 17%, and further volume-based procurement could do more damage. Finally, CSLLY holders carry Australian dollar to US dollar currency exposure on the share price and trade in a thinner OTC market with wider spreads than the ASX line.

We give no verdict on CSL Ltd.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Immunoglobulin recovery at CSL Behring. Immunoglobulin is CSL's single most important product line, at about US$6.2 billion of FY26 sales, and it was flat for the year as CSL worked down excess US channel inventory and absorbed Medicare Part D redesign effects and some prior-year tender losses.

The case against. The most immediate risk is that immunoglobulin demand stays soft or that competitors such as Grifols, Takeda and Octapharma price aggressively, which would undercut the FY27 guidance the recent rebound is built on.

Read the full bull and bear case on CSLLY, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see CSL Ltd.'s investor relations page or your broker.

• Revenue (FY26, year to June 2026): ~US$15.8 billion (down ~1%)
• Underlying NPATA (FY26): ~US$3.1 billion (down ~2%)
• Statutory result (FY26): ~US$2.6 billion loss after ~US$7.1 billion pre-tax impairments
• FY27 guidance: ~5% underlying NPAT growth, revenue broadly flat at constant currency
• ASX price / market value: ~A$185 per share (~US$129), market value ~A$89 billion (~US$62 billion)
• Valuation on underlying earnings: ~20x FY26 NPATA, ~19x on FY27 guidance; dividend yield ~2.3%

CSL reports in US dollars, which makes its earnings directly comparable to the CSLLY price once the four-ADRs-per-share ratio is applied: one ASX share at about A$185 is roughly US$129, or about US$32 per ADR. At around 20 times underlying earnings, CSL trades well below the 30 to 40 times multiple it commanded for most of the last decade, which reflects both slower expected growth and lower confidence after the guidance cuts. FY26 dividends totalled roughly US$2.92 per share (an interim of about US$1.30 and a final of US$1.62), and the company is continuing an on-market buyback of about US$1.1 billion in FY27. The statutory loss is driven by non-cash impairments and restructuring charges, while operating cash flow held near US$3.5 billion.

Other names that sit close to CSLLY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CSLLY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CSLLY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CSLLY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CSL today is a high-quality plasma franchise priced after a year of writedowns, a CEO exit and guidance cuts, so the case rests on immunoglobulin growth returning while Vifor shrinks and Seqirus treads water.

Whether CSLLY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CSLLY a buy or a sell?, and where the stock could go from here in the CSLLY stock forecast.

For income investors, whether CSLLY pays a dividend and how the payout looks is covered in does CSLLY pay a dividend? And to weigh CSLLY against a peer, read the full side-by-side comparisons: CSLLY vs GRFS and CSLLY vs CSL.